GlassScriptPhysician profile
Celeste Ann Saunders
NPI 1043948318
$3,449.87
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $1,667 · 2024: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,202 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,201.61 |
| Education | $137.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $478.12 | 2023-2024 | Caplyta |
| Alkermes, INC. | $446.81 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $434.87 | 2022-2024 | Rexulti |
| Abbvie INC. | $429.03 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $404.56 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $270.98 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $245.94 | 2023-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $159.61 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $124.78 | 2024 | Uzedy |
| Ironshore Pharmaceuticals INC. | $107.37 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.25 | 2022-2024 | Trintellix |
| Indivior INC. | $58.54 | 2024 | Sublocade |
| Almatica Pharma LLC | $49.94 | 2023-2024 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $48.31 | 2024 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $46.72 | 2023 | Spravato |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $43.75 | 2024 | Relexxii |
| Supernus Pharmaceuticals, INC. | $14.29 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.